About PRIVIGEN
Driven by Our Promise™
CSL Behring innovates and collaborates to improve access and care for patients.
About CIDP and PI
Treating primary immunodeficiency (PI) can reduce healthcare utilization costs, and even more cost savings could be realized by shifting care to home-based intravenous immunoglobulin (IVIg) administration.1
Payers are challenged with identifying which home-based therapies are both clinically sound and convenient. Privigen is proven IVIg therapy for PI and chronic inflammatory demyelinating polyneuropathy (CIDP) and the only IVIg formulated with proline for immunoglobulin G stabilization.
CSL Behring has a broad portfolio of immunoglobulin (Ig) products.
Explore more clinical information here.
What is Privigen?
Privigen is an IVIg replacement therapy indicated for the treatment of PI, chronic immune thrombocytopenic purpura (ITP) in patients aged ≥15 years, and CIDP in adults.
Limitation of use: Privigen maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with Privigen in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient's response and demonstrated need for continued therapy.
Please see full prescribing information for Privigen.
What are the key benefits?
CSL Behring has one of the world’s largest and most innovative plasma collection networks with 2 Ig products to meet patient needs: IVIg and subcutaneous immunoglobulin (SCIg).
Rigorous donor screening process
and state-of-the-art manufacturing facilities help enhance the safety of Privigen
Proven efficacy and tolerability
>1 million patient-years of therapy2
Want to learn more?
Meet with your CSL Behring Corporate Account Manager.
Help us help you
Share your thoughts so we can further tailor our content.